CSPC Pharmaceutical Group (CVG) Financial Statements
CSPC Pharmaceutical Group Financial Overview
CSPC Pharmaceutical Group's market cap is currently $10.31B. The company's EPS TTM is $0.65; its P/E ratio is 10.25; and it has a dividend yield of 4.16%. CSPC Pharmaceutical Group is estimated to report earnings on November 13, 2026, and the estimated EPS forecast is $0.01. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 25.33B | $ 29.54B | $ 31.47B | $ 31.59B | $ 27.41B |
| Gross Profit | $ 16.62B | $ 20.67B | $ 22.19B | $ 22.73B | $ 20.79B |
| Operating Income | $ 3.87B | $ 5.45B | $ 7.01B | $ 6.93B | $ 6.14B |
| EBITDA | $ 5.24B | $ 7.16B | $ 8.59B | $ 8.83B | $ 7.58B |
| Net Income | $ 3.78B | $ 4.41B | $ 5.88B | $ 6.22B | $ 5.51B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 8.87B | $ 7.75B | $ 13.09B | $ 13.87B | $ 10.73B |
| Total Assets | $ 46.72B | $ 44.36B | $ 46.28B | $ 41.18B | $ 34.68B |
| Total Debt | $ 641.38M | $ 507.33M | $ 706.90M | $ 582.54M | $ 93.87M |
| Net Debt | $ -5.45B | $ -5.86B | $ -11.31B | $ -9.72B | $ -9.17B |
| Total Liabilities | $ 12.15B | $ 10.52B | $ 11.26B | $ 10.06B | $ 7.91B |
| Stockholders' Equity | $ 33.19B | $ 32.24B | $ 33.20B | $ 29.77B | $ 25.94B |
| Cash Flow | |||||
| Free Cash Flow | $ 3.99B | $ 1.74B | $ 2.29B | $ 6.62B | $ 2.88B |
| Operating Cash Flow | $ 5.90B | $ 4.53B | $ 4.18B | $ 8.10B | $ 4.64B |
| Investing Cash Flow | $ -4.13B | $ -4.41B | $ 607.27M | $ -7.19B | $ -637.33M |
| Financing Cash Flow | $ -2.44B | $ -5.11B | $ -2.30B | $ -1.95B | $ -2.20B |
Currency in CNY
